AbbVie has been granted a patent for a method of treating spondyloarthropathy, including rheumatoid arthritis and various spondyloarthritic conditions. The method involves orally administering a tablet containing a specific compound, (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, in a therapeutically effective amount of 15 mg, once daily to the patient. GlobalData’s report on AbbVie gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights AbbVie Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AbbVie, Peptide pharmacophores was a key innovation area identified from patents. AbbVie's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for a method of treating spondyloarthropathy with a tablet

Source: United States Patent and Trademark Office (USPTO). Credit: AbbVie Inc

A recently granted patent (Publication Number: US11773106B2) discloses a method for treating spondyloarthropathy in human patients. The method involves orally administering a tablet containing a specific compound, (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1), once daily. The tablet should contain a therapeutically effective amount of 15 mg of Compound 1.

The method is particularly applicable to adult patients who have shown an inadequate response or intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) or anti-TNF biologic agents. Spondyloarthropathy, specifically ankylosing spondylitis, is the targeted condition for treatment.

In addition to the specific dosage and patient criteria, the patent also mentions the use of a specific form of Compound 1, known as Freebase Hydrate Form C. This form is administered as 15.4 mg and has a distinct X-ray powder diffraction pattern characterized by peaks at 13.4±0.2, 15.1±0.2, 15.5±0.2, 17.0±0.2, 20.9±0.2, and 21.7±0.2 degrees two theta when measured at about 25° C. with monochromatic Ka1 radiation.

The method claims to result in an Assessment of SpondyloArthritis International Society 20 (ASAS20) response at 14 weeks after the first daily administration. ASAS20 is a measure of treatment response in spondyloarthropathy patients, indicating a significant improvement in symptoms.

Furthermore, the patent also includes a variant of the method, referred to as claim 10, which aims to achieve an Assessment of SpondyloArthritis International Society 40 (ASAS40) response at 14 weeks after the first daily administration. ASAS40 represents an even higher level of treatment response, indicating a greater improvement in symptoms.

Overall, this granted patent presents a method for treating spondyloarthropathy, specifically ankylosing spondylitis, in adult patients who have not responded well to NSAIDs or anti-TNF biologic agents. The method involves the oral administration of a tablet containing a specific compound, Compound 1, in a therapeutically effective amount of 15 mg. The patent claims that this treatment leads to significant improvements in symptoms, as measured by ASAS20 or ASAS40 response at 14 weeks.

To know more about GlobalData’s detailed insights on AbbVie, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies